英文原文:Lundbeck Canada Inc. Announces Health Canada Approval of Trintellix? (vortioxetine hydrobromide) for Treatment of Adults with Major Depressive Disorder
MONTREAL, Oct. 28, 2014 /CNW/ - Lundbeck Canada Inc. announced today that Health Canada has approved TrintellixTM (vortioxetine hydrobromide) for the treatment of major depressive disorder (MDD), a debilitating mental health illness which affects more than 1 in 10 Canadians over the age of 181 and occurs about twice as often in women than in men1,2,3.
"MDD manifests itself through a wide array of emotional, physical and cognitive symptoms. Beyond the mood component, changes in appetite and psychomotor activity, difficulty concentrating and making decisions, or even suicidal behaviour, are common. These symptoms can be felt by sufferers on a daily basis, often throughout the day, and seriously impede their ability to function" says Dr. Roger McIntyre, Full Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network. "With such a diverse group of symptoms, it is important to find diversity in treatment to improve patient outcomes."
About TrintellixTM
Trintellix is a novel agent indicated for the treatment of major depressive disorder (MDD) in adults. Trintellix is an inhibitor of serotonin (5-HT) reuptake and also an agonist at 5-HT1A receptors, a partial agonist at 5-HT1B receptors and an antagonist at 5-HT3, 5-HT1D and 5-HT7 receptors. The efficacy of Trintellix in providing symptomatic relief of MDD was demonstrated in controlled clinical trials. The efficacy of Trintellix in maintaining an antidepressant response for up to 24 weeks was demonstrated in a controlled trial in patients with MDD who initially responded to an acute, open label treatment with Trintellix.4
"One can hope for better management of MDD symptoms, or one can act," says Patrick Cashman, President and General Manager of Lundbeck Canada Inc. "With the approval of Trintellix by Health Canada, we strive to offer new alternatives to Canadian patients living with MDD who deserve better treatment. This is why we keep pushing boundaries, trying to improve the daily lives of people who live with mental illness."
Trintellix will be made available in Canada by December 2014.
Burden of Depression
According to The World Health Organization, fewer than half of people with depression worldwide are receiving treatment5, and the burden of depression is expected to continue to rise globally6. For those who do seek treatment, discontinuation is not uncommon7,8. MDD is a heterogeneous disorder that does not consistently respond to therapy, thus it's important for patients to work with a healthcare provider to help find a treatment plan that works for them9.作者: Eric.Liu 时间: 14-10-31 13:21
嗨,我还以为中国会上市呢作者: 小丁 时间: 14-11-1 00:28
沃替西汀~半年多前就嚷嚷上咧~换汤汤不换药药~